Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Trends

Report ID: GMI7991
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Acute Myeloid Leukemia Market Trends

Surging government initiatives and polices play a pivotal role in driving the acute myeloid leukemia industry. Also, increased government funding for medical research, including acute myeloid leukemia research, drive advancements in understanding the molecular basis of AML, leading to the development of innovative therapies and treatment modalities.
For instance, The National Cancer Institute (NCI), in 2023, has funded USD 43.3 million to Ohio State University and New York University to build precision oncology approaches for the treatment of AML by identifying genetic variants and other genomic factors.
This government initiatives aimed at strengthening healthcare infrastructure that can enhance the care for AML patients. This includes investments in medical facilities, equipment, and training for healthcare professionals.

However, innovative and targeted therapies for AML often come with a high price tag. The cost of these novel treatments may limit access for certain patients, particularly in regions or healthcare systems with limited financial resources. Thus, impeding the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for acute myeloid leukemia was valued at USD 2.1 billion in 2023 and is estimated to observe 10.7% CAGR between 2024 and 2032, attributed to advancement in technology, surging government initiatives, early diagnosis, coupled with efforts to implement screening programs.

The hospitals & clinics segment dominated the market in 2023 and is anticipated to record 9.8% CAGR from 2024 to 2032 as they are equipped with comprehensive facilities and specialized departments, including hematology-oncology units, where AML patients can receive integrated care.

In 2023, North America market for acute myeloid leukemia held a significant share of 38.4% and will grow rapidly through 2032 as the region boasts advanced healthcare infrastructure, including state-of-the-art hospitals, research facilities, and specialized cancer treatment centers.

Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Partner Therapeutics, Inc., Pfizer Inc., and Rigel Pharmaceuticals, Inc.